ESMO进入倒计时，高弹性港股通创新药ETF（520880）冲高2%！

Core Viewpoint - The Hong Kong stock market's innovative drug sector is experiencing significant gains, with the Hong Kong Stock Connect Innovative Drug ETF (520880) showing strong performance and attracting substantial investment [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) saw a rise of nearly 6% led by Ascentage Pharma-B, with several other stocks like Kelun-B and Sangamo Therapeutics also rebounding over 4% [1]. - The ETF recorded a trading volume exceeding 340 million yuan, with a peak intraday increase of 2% [1]. - The ETF has attracted over 129 million yuan in net subscriptions during recent dips, indicating strong buying interest [1]. Group 2: Upcoming Events - The ESMO (European Society for Medical Oncology) 2025 annual meeting is scheduled for October 17-21 in Berlin, where multiple Chinese innovative drug companies are expected to announce breakthrough clinical research results in areas such as kidney and lung cancer [3]. Group 3: Liquidity and Economic Context - The recent dovish stance from the Federal Reserve, with Chairman Powell hinting at the possibility of an interest rate cut in October, may create a favorable environment for the Chinese pharmaceutical sector [3]. - The innovative drug sector is anticipated to benefit from increased collaboration and business development (BD) activities, as evidenced by a recent deal by Innovent Biologics involving a $100 million upfront payment and a total deal value exceeding $2 billion [3]. Group 4: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) exclusively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which is 100% focused on innovative drug research and development, excluding CXO companies [4]. - As of the end of September, the fund size of the ETF was 1.806 billion yuan, with an average daily trading volume of 493 million yuan, making it the largest and most liquid ETF in its category [6].